|
Market Closed -
NYSE
16:00:03 2026-08-25 EDT
|
After hours 19:56:36 | |||
| 92.90 USD | -1.29% |
|
93.14 | +0.26% |
| 08-25 | HHS Plans 2 New FDA Deputy Commissioner Roles Covering Drugs, Technology | MT |
| 08-25 | HHS Plans 2 New FDA Deputy Commissioner Roles Covering Drugs, Technology, CNBC Reports | MT |
| Market Cap | 119B 102B 95.4B 87.14B 164B 11,327B 166B 1,125B 438B 5,715B 446B 436B 18,926B | P/E 2026 * |
13.7x | P/E 2027 * | 13.1x |
|---|---|---|---|---|---|
| Enterprise Value | 171B 146B 137B 125B 236B 16,277B 239B 1,617B 629B 8,212B 641B 627B 27,195B | EV / Sales 2026 * |
0.41x | EV / Sales 2027 * | 0.39x |
| Free-Float |
71.17% | Yield 2026 * |
2.86% | Yield 2027 * | 2.95% |
Last Transcript: CVS Health Corporation
| 1 day | +0.26% | ||
| 1 week | -2.12% | ||
| Current month | -11.04% | ||
| 1 month | -13.77% | ||
| 3 months | -0.39% | ||
| 6 months | +21.93% | ||
| Current year | +17.06% |
| 1 week | 92.35 |  | 94.39 |
| 1 month | 92.35 | | 110 |
| Current year | 69.51 | | 110.68 |
| 1 year | 69.51 | | 110.68 |
| 3 years | 43.56 | | 110.68 |
| 5 years | 43.56 | | 111.25 |
| 10 years | 43.56 | | 111.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
J. Joyner
CEO | Chief Executive Officer | 62 | 2024-10-16 |
Ali Keshavarz
PSD | President | - | - |
Brian Newman
DFI | Director of Finance/CFO | 57 | 2025-05-11 |
| Director | Title | Age | Since |
|---|---|---|---|
C. Brown
BRD | Director/Board Member | 74 | 2007-02-28 |
Anne Finucane
BRD | Director/Board Member | 73 | 2011-01-19 |
| Director/Board Member | 71 | 2015-03-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 5/14/26 | Free | Director | 1,737 | 0.0001% | ||
| 2/28/26 | Tax | Executive/Senior Manager | 7,886 | 0.0006% | ||
| 2/28/26 | Tax | Chief Executive Officer | 1,944 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.29% | -2.12% | +30.46% | +38.00% | 119B | |
| -0.11% | +4.14% | +6.45% | +56.89% | 92.83B | |
| +0.80% | -1.89% | -3.12% | +56.25% | 30.13B | |
| +0.26% | +3.50% | +36.86% | +84.69% | 26.99B | |
| -2.41% | +0.62% | +50.85% | +266.27% | 21.89B | |
| -0.29% | +0.67% | -1.64% | -5.81% | 22.44B | |
| +4.49% | +9.94% | -3.94% | +23.49% | 15.27B | |
| +0.30% | -1.12% | -7.31% | -8.91% | 12.48B | |
| +0.74% | -0.06% | +29.47% | +76.72% | 11.34B | |
| -0.36% | +1.54% | -4.42% | +33.91% | 10.36B | |
| Average | +0.37% | +1.68% | +13.37% | +62.15% | 36.25B | |
| Weighted average by Cap. | +0.19% | +1.07% | +17.47% | +57.77% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 418B 358B 335B 306B 578B 39,824B 584B 3,956B 1,540B 20,092B 1,568B 1,534B 66,539B | 430B 368B 345B 315B 595B 40,948B 600B 4,068B 1,584B 20,659B 1,613B 1,578B 68,417B |
| Net income | 8.79B 7.54B 7.06B 6.45B 12.17B 838B 12.29B 83.3B 32.43B 423B 33.02B 32.3B 1,401B | 9.11B 7.81B 7.31B 6.68B 12.61B 869B 12.73B 86.28B 33.59B 438B 34.21B 33.46B 1,451B |
| Net Debt | 51.92B 44.49B 41.68B 38.08B 71.86B 4,949B 72.57B 492B 191B 2,497B 195B 191B 8,269B | 49.15B 42.11B 39.46B 36.05B 68.03B 4,685B 68.7B 465B 181B 2,364B 185B 181B 7,828B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-25 | US$92.90 | -1.29% | 4,102,481 |
| 26-08-24 | US$94.11 | +1.17% | 9,231,692 |
| 26-08-21 | US$93.02 | -0.67% | 5,592,453 |
| 26-08-20 | US$93.65 | 0.00% | 6,439,680 |
| 26-08-19 | US$93.65 | -1.33% | 6,351,620 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CVS Stock
Select your edition
All financial news and data tailored to specific country editions
